
News|Articles|July 21, 2020
AstraZeneca and IQVIA Partner on Potential COVID-19 Vaccine
Author(s)Pharmaceutical Technology Editors
The project will focus on providing a faster route to clinical studies for AstraZeneca’s potential COVID-19 vaccine, AZD1222.
Advertisement
AstraZeneca and IQVIA, a Durham, NC-based advanced analytics and technology solutions provider, announced they are teaming up to develop a potential new vaccine for COVID-19 as part of the US government’s Operation Warp Speed project.
The project will focus on providing a faster route to clinical studies for AstraZeneca’s potential COVID-19 vaccine, AZD1222, according to a July 14, 2020 press release. The initiative will also include a subject study which will utilize IQVIA’s virtual trial solutions.
Source:
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Renewing Prosaic Generics for Cancer Treatment
2
Leveraging an Innovative Mid-Scale Manufacturing Solution to Meet Diverse Needs
3
Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance
4
Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory Landscape
5




